Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.46 |
| ▸ | MMP14 | P50281 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155060 | 0.90 | MMP13 (0.60) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL2155241 | 0.88 | MMP13 (0.48) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL2155965 | 0.84 | MMP13 (0.49) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL2155359 | 0.83 | ATM (0.40) | ATMALDH1A1TSHRHTTLMNA | |
| SCHEMBL2155126 | 0.82 | ATM (0.43) | ATMALDH1A1TSHRHTTLMNA | |
| SCHEMBL12463700 | 0.80 | MMP13 (0.53) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL2155429 | 0.80 | MMP7 (0.55) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL5513510 | 0.79 | ALDH1A1 (0.41) | ATMALDH1A1TSHRHTTLMNA | |
| SCHEMBL2154774 | 0.79 | MMP13 (0.64) | MMP13MMP14CYP3A4ADAMTS4KCNH2 | |
| SCHEMBL5513512 | 0.78 | LMNA (0.42) | ATMALDH1A1TSHRHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | claimed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | claimed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | claimed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | claimed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | MMP13 2288/4885MMP14 2295/4885CYP3A4 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.